EUCTR2009-012947-40-DK进行中（未招募）1 期
BREATHER (PENTA 16): Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV - BREATHER
PENTA Foundation0 个研究点目标入组 220 人开始时间: 2011年12月6日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •HIV-1 infected young people aged 8 to 24 years inclusive (Young people recruited between the ages of 16-24 must either be in regular physical contact with their clinician or be able to transfer to an adult physician at the same site for follow-up or to an affiliated adult site).
- •Parents/carers and/or young people, where applicable, willing to provide informed consent.
- •On a stable first-line ART treatment containing at least 2 NRTIs/NtRTIs and EFV for at least 12 months and willing to continue the regimen throughout the study period. Young people on regimens containing nevirapine (NVP) or a boosted protease inhibitor with undetectable viral load for over one year who wish to enrol should switch to EFV. Once they are stable on the EFV containing regimen for more than 12 weeks they may be enrolled (must have 2 subsequent HIV-1 RNA measurements <50 c/ml over a minimum period of 12 weeks). Previous dual therapy and/or substitution of NRTIs is allowed providing any changes were not for disease progression, immunological or virological failure (where virological failure is defined as two successive HIV-1 RNA results>1000 c/ml) subsequent to virological control having been achieved on ART.
- •Viral suppression (HIV-1 RNA <50 c/ml) for at least the prior 12 months (at least the last 3 measurements, including screening): young people who have experienced a single viral load >50 but <1000 copies/ml (preceded and followed by VL<50 c/ml) in the last 12 months can be enrolled.
- •CD4 cell count =350 106/L at screening visit.
- •Centre must routinely use an assay which detects HIV RNA-1 viral load =50 c/ml.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 199
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 199
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnancy or risk of pregnancy in females of child bearing potential.
- •Acute illness (young people may be enrolled after illness).
- •Receiving concomitant therapy for an acute illness (young people may be enrolled after finishing therapy).
- •A creatinine, AST or ALT of grade 3 or above at screening.
- •On a regimen including nevirapine or a boosted PI (young people may switch to an EFV based regimen).
- •Previous ART monotherapy (except for the prevention of mother-to-child transmission)
研究者
相似试验
进行中（未招募）
1 期
BREATHER (PENTA 16): Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIVInfection HIV-1MedDRA version: 16.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2009-012947-40-BEPENTA Foundation220
进行中（未招募）
1 期
BREATHER (PENTA 16): Short-cycle therapy (SCT) (5 days on/ 2 days off) in young people with chronic HIV-infection - BREATHER(PENTA 16) Trial: Short-Cycle Therapy(SCT)EUCTR2009-012947-40-GBPENTA Foundation199
进行中（未招募）
1 期
BREATHER (PENTA 16): Short-cycle therapy (SCT) (5 days on/ 2 days off) in young people with chronic HIV-infectioHIV-1 InfectionMedDRA version: 17.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2009-012947-40-DEPENTA Foundation160
进行中（未招募）
1 期
BREATHER (PENTA 16): Short-cycle therapy (SCT) (5 days on/ 2 days off) in young people with chronic HIV-infection - BREATHER(PENTA 16) Trial: Short-Cycle Therapy(SCT)HIV-1 InfectionMedDRA version: 16.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2009-012947-40-IEPENTA Foundation160
Unknown
2 期
BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infectionHIVNCT01641016PENTA Foundation160